Your browser doesn't support javascript.
loading
Inherited GATA2 Deficiency Is Dominant by Haploinsufficiency and Displays Incomplete Clinical Penetrance.
Oleaga-Quintas, Carmen; de Oliveira-Júnior, Edgar Borges; Rosain, Jérémie; Rapaport, Franck; Deswarte, Caroline; Guérin, Antoine; Sajjath, Sairaj Munavar; Zhou, Yu Jerry; Marot, Stéphane; Lozano, Claire; Branco, Lidia; Fernández-Hidalgo, Nuria; Lew, Dukhee Betty; Brunel, Anne-Sophie; Thomas, Caroline; Launay, Elise; Arias, Andrés Augusto; Cuffel, Alexis; Monjo, Vanesa Cunill; Neehus, Anna-Lena; Marques, Laura; Roynard, Manon; Moncada-Vélez, Marcela; Gerçeker, Bengü; Colobran, Roger; Vigué, Marie-Gabrielle; Lopez-Herrera, Gabriela; Berron-Ruiz, Laura; Méndez, Nora Hilda Segura; O'Farrill Romanillos, Patricia; Le Voyer, Tom; Puel, Anne; Bellanné-Chantelot, Christine; Ramirez, Kacy A; Lorenzo-Diaz, Lazaro; Alejo, Noé Ramirez; de Diego, Rebeca Pérez; Condino-Neto, Antonio; Mellouli, Fethi; Rodriguez-Gallego, Carlos; Witte, Torsten; Restrepo, José Franco; Jobim, Mariana; Boisson-Dupuis, Stéphanie; Jeziorski, Eric; Fieschi, Claire; Vogt, Guillaume; Donadieu, Jean; Pasquet, Marlène; Vasconcelos, Julia.
Afiliación
  • Oleaga-Quintas C; Laboratory of Human Genetics of Infectious Diseases, INSERM U1163, Necker Hospital for Sick Children, 24 Boulevard du Montparnasse, Paris, France.
  • de Oliveira-Júnior EB; University of Paris, Imagine Institute, Paris, France.
  • Rosain J; Department of Immunology, School of Medicine, Complutense University, Madrid, Spain.
  • Rapaport F; Laboratory of Human Genetics of Infectious Diseases, INSERM U1163, Necker Hospital for Sick Children, 24 Boulevard du Montparnasse, Paris, France.
  • Deswarte C; University of Paris, Imagine Institute, Paris, France.
  • Guérin A; Department of Immunology, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, SP, Brazil.
  • Sajjath SM; Laboratory of Human Genetics of Infectious Diseases, INSERM U1163, Necker Hospital for Sick Children, 24 Boulevard du Montparnasse, Paris, France.
  • Zhou YJ; University of Paris, Imagine Institute, Paris, France.
  • Marot S; St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA.
  • Lozano C; Laboratory of Human Genetics of Infectious Diseases, INSERM U1163, Necker Hospital for Sick Children, 24 Boulevard du Montparnasse, Paris, France.
  • Branco L; University of Paris, Imagine Institute, Paris, France.
  • Fernández-Hidalgo N; Laboratory of Human Genetics of Infectious Diseases, INSERM U1163, Necker Hospital for Sick Children, 24 Boulevard du Montparnasse, Paris, France.
  • Lew DB; University of Paris, Imagine Institute, Paris, France.
  • Brunel AS; Department of Microbiology and Immunology, Columbia University Medical Center, New York, NY, USA.
  • Thomas C; Department of Microbiology and Immunology, Columbia University Medical Center, New York, NY, USA.
  • Launay E; Center for the Study of Primary Immunodeficiencies, AP-HP, Necker Hospital for Sick Children, Paris, France.
  • Arias AA; Center for the Study of Primary Immunodeficiencies, AP-HP, Necker Hospital for Sick Children, Paris, France.
  • Cuffel A; Department of Immunology, Porto Hospital Center, Porto, Portugal.
  • Monjo VC; Service of Infectious Diseases, University Hospital Vall d'Hebron, Barcelona, Spain.
  • Neehus AL; The Children's Foundation Research Center and Department of Pediatrics, College of Medicine, University of Tennessee, Memphis, TN, USA.
  • Marques L; Infectious Diseases Unit, Montpellier, France.
  • Roynard M; Pediatric Oncology and Hematology, University Hospital of Nantes, Nantes, France.
  • Moncada-Vélez M; Pediatric Oncology and Hematology, University Hospital of Nantes, Nantes, France.
  • Gerçeker B; St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA.
  • Colobran R; Primary Immunodeficiencies Group, Department of Microbiology and Parasitology, School of Medicine, University of Antioquia UdeA, Medellin, Colombia.
  • Vigué MG; School of Microbiology, University of Antioquia UdeA, Medellin, Colombia.
  • Lopez-Herrera G; Center for the Study of Primary Immunodeficiencies, AP-HP, Necker Hospital for Sick Children, Paris, France.
  • Berron-Ruiz L; Department of Immunology, Son Espases Hospital, Palma de Mallorca, Spain.
  • Méndez NHS; Laboratory of Human Genetics of Infectious Diseases, INSERM U1163, Necker Hospital for Sick Children, 24 Boulevard du Montparnasse, Paris, France.
  • O'Farrill Romanillos P; University of Paris, Imagine Institute, Paris, France.
  • Le Voyer T; Department of Pediatrics, Porto Hospital Center, Porto, Portugal.
  • Puel A; Laboratory of Human Genetics of Infectious Diseases, INSERM U1163, Necker Hospital for Sick Children, 24 Boulevard du Montparnasse, Paris, France.
  • Bellanné-Chantelot C; University of Paris, Imagine Institute, Paris, France.
  • Ramirez KA; St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA.
  • Lorenzo-Diaz L; Department of Dermatology, Ege University Medical Faculty, Izmir, Turkey.
  • Alejo NR; Immunology Division, Hospital Universitari Vall d'Hebron (HUVH), Jeffrey Model Foundation Excellence Center, Barcelona, Spain.
  • de Diego RP; Vall d'Hebron Research Institute (VHIR), Barcelona, Spain.
  • Condino-Neto A; Department of Cell Biology, Physiology and Immunology, Autonomous University of Barcelona (UAB), Barcelona, Spain.
  • Mellouli F; Area of Clinical and Molecular Genetics, University Hospital Vall d'Hebron, Barcelona, Spain.
  • Rodriguez-Gallego C; Infectious Diseases Unit, Montpellier, France.
  • Witte T; Immunodeficiencies Research Unit at the National Institute of Pediatrics, Mexico City, Mexico.
  • Restrepo JF; Immunodeficiencies Research Unit at the National Institute of Pediatrics, Mexico City, Mexico.
  • Jobim M; Allergy and Clinical Immunology Service at the XXI Century National Medical Center, Mexican Institute of Social Security (IMSS), Mexico City, Mexico.
  • Boisson-Dupuis S; Allergy and Clinical Immunology Service at the XXI Century National Medical Center, Mexican Institute of Social Security (IMSS), Mexico City, Mexico.
  • Jeziorski E; Laboratory of Human Genetics of Infectious Diseases, INSERM U1163, Necker Hospital for Sick Children, 24 Boulevard du Montparnasse, Paris, France.
  • Fieschi C; University of Paris, Imagine Institute, Paris, France.
  • Vogt G; Laboratory of Human Genetics of Infectious Diseases, INSERM U1163, Necker Hospital for Sick Children, 24 Boulevard du Montparnasse, Paris, France.
  • Donadieu J; University of Paris, Imagine Institute, Paris, France.
  • Pasquet M; St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA.
  • Vasconcelos J; Department of Genetics, DMU BioGeM, Pitié Salpetrière Hospital, AP-HP, Paris, France.
J Clin Immunol ; 41(3): 639-657, 2021 04.
Article en En | MEDLINE | ID: mdl-33417088
PURPOSE: Germline heterozygous mutations of GATA2 underlie a variety of hematological and clinical phenotypes. The genetic, immunological, and clinical features of GATA2-deficient patients with mycobacterial diseases in the familial context remain largely unknown. METHODS: We enrolled 15 GATA2 index cases referred for mycobacterial disease. We describe their genetic and clinical features including their relatives. RESULTS: We identified 12 heterozygous GATA2 mutations, two of which had not been reported. Eight of these mutations were loss-of-function, and four were hypomorphic. None was dominant-negative in vitro, and the GATA2 locus was found to be subject to purifying selection, strongly suggesting a mechanism of haploinsufficiency. Three relatives of index cases had mycobacterial disease and were also heterozygous, resulting in 18 patients in total. Mycobacterial infection was the first clinical manifestation in 11 patients, at a mean age of 22.5 years (range: 12 to 42 years). Most patients also suffered from other infections, monocytopenia, or myelodysplasia. Strikingly, the clinical penetrance was incomplete (32.9% by age 40 years), as 16 heterozygous relatives aged between 6 and 78 years, including 4 older than 60 years, were completely asymptomatic. CONCLUSION: Clinical penetrance for mycobacterial disease was found to be similar to other GATA2 deficiency-related manifestations. These observations suggest that other mechanisms contribute to the phenotypic expression of GATA2 deficiency. A diagnosis of autosomal dominant GATA2 deficiency should be considered in patients with mycobacterial infections and/or other GATA2 deficiency-related phenotypes at any age in life. Moreover, all direct relatives should be genotyped at the GATA2 locus.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Fenotipo / Penetrancia / Predisposición Genética a la Enfermedad / Estudios de Asociación Genética / Haploinsuficiencia / Deficiencia GATA2 Tipo de estudio: Diagnostic_studies / Etiology_studies / Prognostic_studies Límite: Adolescent / Adult / Child / Female / Humans / Male / Middle aged Idioma: En Revista: J Clin Immunol Año: 2021 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Fenotipo / Penetrancia / Predisposición Genética a la Enfermedad / Estudios de Asociación Genética / Haploinsuficiencia / Deficiencia GATA2 Tipo de estudio: Diagnostic_studies / Etiology_studies / Prognostic_studies Límite: Adolescent / Adult / Child / Female / Humans / Male / Middle aged Idioma: En Revista: J Clin Immunol Año: 2021 Tipo del documento: Article País de afiliación: Francia